IgA Nephropathy

Clinical Trial, Therapeutic Indication

VOYXACT Preserves Kidney Function at Two Years in IgA Nephropathy

Otsuka presented complete 24-month Phase III VISIONARY results showing a prespecified annualized eGFR slope of +0.3 mL m²/year with VOYXACT versus −4.2 with placebo, a treatment difference of +4.5 with p

admin
August 3, 2026

All categories, Technology Modalities

First BAFF/APRIL Dual Inhibitor Validates B-Cell Survival Pathway

The U.S. FDA granted accelerated approval to TRUTAKNA™ (atacicept-vymj) for adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. Developed by Vera Therapeutics, TRUTAKNA is the first therapy to simultaneously…

admin
July 7, 2026

VOYXACT Preserves Kidney Function at Two Years in IgA Nephropathy

First BAFF/APRIL Dual Inhibitor Validates B-Cell Survival Pathway

Saturday Rounds